What criteria is needed in relapsed/refractory B-cell ALL to choose CAR-T therapy over conventional stem cell transplant as destination therapy?

Currently, there are no standard criteria used to choose CAR-T over conventional stem cell transplant as destination therapy. However, there are many factors that often push us in one direction or the other. As we learn more about outcomes after CAR-T cell therapy, there are many factors we know are...

In my opinion, the evidence that exists to support CAR-T as “destination therapy” for adults with relapsed/refractory B-ALL is still weak. There are clearly some patients who can achieve and remain in remission after these therapies, some of which have persisted well beyond 1 year (e.g., Shah et al....

In adult patients who are transplant-naïve, we continue to favor consolidation with allogeneic stem cell transplantation following a response to CAR T-cell therapy. However, there are several factors that may be interplayed with the decision, including patient and disease characteristics, quality of...